{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:55Z","timestamp":1788441175925,"version":"build-2803163510"},"reference-count":48,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Atherosclerotic cardiovascular disease (ASCVD) is associated with increased morbidity and mortality rates. Numerous studies have shown that lowering low-density lipoprotein cholesterol (LDL-C) levels can reduce the occurrence of cardiovascular disease (CVD). Current data indicate that 80% of patients with ASCVD do not achieve the LDL-C targets recommended by clinical guidelines. Nearly 15% of patients with hypercholesterolemia exhibit statin intolerance, with some experiencing severe adverse reactions such as liver function abnormalities and rhabdomyolysis. Statins require daily administration, and proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies should be injected 12 to 26 times annually. Frequent dosing reduces patient adherence. This review comprehensively discusses inclisiran, the first lipid-lowering small interfering RNA (siRNA) drug, focusing on the associated mechanism of action, pharmacology, clinical trial data, efficacy, safety, use in special populations, and adverse effects. The objective is to provide evidence to guide the appropriate clinical use of inclisiran, a novel option for lipid-lowering therapy. Inclisiran may represent another milestone in the treatment of dyslipidemia.<\/jats:p>","DOI":"10.31083\/rcm48237","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:17:46Z","timestamp":1788437866000},"source":"Crossref","is-referenced-by-count":0,"title":["A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4766-7139","authenticated-orcid":true,"given":"Xuebing","family":"Wu","sequence":"first","affiliation":[{"name":"Electrocardiogram Room, Yantai Yuhuangding Hospital, 264000 Yantai, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0155-4451","authenticated-orcid":true,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Norman Bethune Hospital of Jilin University, 130000 Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of Clinical Lipidology. 2023; 17: 392\u2013400.","DOI":"10.1016\/j.jacl.2023.04.010"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (London, England). 2016; 388: 2532\u20132561.","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Fitchett DH, Hegele RA, Verma S. Statin Intolerance. Circulation. 2015; 131: e389\u2013e391.","DOI":"10.1161\/circulationaha.114.013189"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013; 158: 526\u2013534.","DOI":"10.7326\/0003-4819-158-7-201304020-00004"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016; 255: 200\u2013209.","DOI":"10.1016\/j.atherosclerosis.2016.09.004"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Di Girolamo FG, Pellin L, Roni C, Biolo G, Sinagra G, Fabris E. Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice. European Journal of Internal Medicine. 2025; 140: 106442.","DOI":"10.1016\/j.ejim.2025.106442"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: Looking beyond LDL regulation. European Journal of Clinical Investigation. 2021; 51: e13459.","DOI":"10.1111\/eci.13459"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW. Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Frontiers in Cardiovascular Medicine. 2021; 8: 764038.","DOI":"10.3389\/fcvm.2021.764038"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Sundararaman SS, Peters LJF, Nazir S, Marquez AB, Bouma JE, Bayasgalan S, et al. PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo. International Journal of Molecular Sciences. 2021; 22: 13026.","DOI":"10.3390\/ijms222313026"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annual Review of Medicine. 2018; 69: 133\u2013145.","DOI":"10.1146\/annurev-med-042716-091351"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. Journal of the American Heart Association. 2022; 11: e023328.","DOI":"10.1161\/JAHA.121.023328"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Seidah NG, Gar\u00e7on D. Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond. Current Atherosclerosis Reports. 2022; 24: 821\u2013830.","DOI":"10.1007\/s11883-022-01057-z"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Keeter WC, Carter NM, Nadler JL, Galkina EV. The AAV-PCSK9 murine model of atherosclerosis and metabolic dysfunction. European Heart Journal Open. 2022; 2: oeac028.","DOI":"10.1093\/ehjopen\/oeac028"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Migliorati JM, Jin J, Zhong XB. siRNA drug Leqvio (inclisiran) to lower cholesterol. Trends in Pharmacological Sciences. 2022; 43: 455\u2013456.","DOI":"10.1016\/j.tips.2022.02.003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovascular Diabetology. 2022; 21: 107.","DOI":"10.1186\/s12933-022-01542-4"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Raghavan S, Singh NK, Gali S, Mani AM, Rao GN. Protein Kinase C\u03b8 Via Activating Transcription Factor 2-Mediated CD36 Expression and Foam Cell Formation of Ly6Chi Cells Contributes to Atherosclerosis. Circulation. 2018; 138: 2395\u20132412.","DOI":"10.1161\/CIRCULATIONAHA.118.034083"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang Z, Chen X, Liu J, Wang Y, Zhang S. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPAR\u03b3 pathway. Autoimmunity. 2022; 55: 223\u2013232.","DOI":"10.1080\/08916934.2022.2051142"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunological Reviews. 2011; 243: 206\u2013214.","DOI":"10.1111\/j.1600-065X.2011.01044.x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, Vajjhala PR, et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death and Differentiation. 2013; 20: 1149\u20131160.","DOI":"10.1038\/cdd.2013.37"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death & Disease. 2018; 9: 171.","DOI":"10.1038\/s41419-017-0257-3"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Xing SS, Yang J, Li WJ, Li J, Chen L, Yang YT, et al. Salidroside Decreases Atherosclerosis Plaque Formation via Inhibiting Endothelial Cell Pyroptosis. Inflammation. 2020; 43: 433\u2013440.","DOI":"10.1007\/s10753-019-01106-x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kong N, Xu Q, Cui W, Feng X, Gao H. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Annals of Translational Medicine. 2022; 10: 1205.","DOI":"10.21037\/atm-22-4652"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. The New England Journal of Medicine. 2017; 376: 1430\u20131440.","DOI":"10.1056\/NEJMoa1615758"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiology. 2019; 4: 1067\u20131075.","DOI":"10.1001\/jamacardio.2019.3502"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. The Lancet. Diabetes & Endocrinology. 2023; 11: 109\u2013119.","DOI":"10.1016\/S2213-8587(22)00353-9"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine. 2020; 382: 1507\u20131519.","DOI":"10.1056\/NEJMoa1912387"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Research. 2024; 120: 1400\u20131410.","DOI":"10.1093\/cvr\/cvae109"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Taub PR, Gutierrez A, Wewers D, Garcia Cantu E, Cao H, Deck C, et al. Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. Journal of the American College of Cardiology. 2025; 86: 196\u2013208.","DOI":"10.1016\/j.jacc.2025.04.049"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal. 2013; 34: 3478\u20133490a.","DOI":"10.1093\/eurheartj\/eht273"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. Journal of the American College of Cardiology. 2020; 75: 2553\u20132566.","DOI":"10.1016\/j.jacc.2020.03.057"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nature Reviews. Cardiology. 2019; 16: 9\u201320.","DOI":"10.1038\/s41569-018-0052-6"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. The New England Journal of Medicine. 2020; 382: 1520\u20131530.","DOI":"10.1056\/NEJMoa1913805"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. European Heart Journal. 2023; 44: 2277\u20132291.","DOI":"10.1093\/eurheartj\/ehad197"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020; 141: 1742\u20131759.","DOI":"10.1161\/CIRCULATIONAHA.119.044795"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Wiegman A, Peterson AL, Hegele RA, Bruckert E, Schweizer A, Lesogor A, et al. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. Circulation. 2025; 151: 1758\u20131766.","DOI":"10.1161\/CIRCULATIONAHA.124.073233"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Bourbon M, Alves AC, Alonso R, Mata N, Aguiar P, Padr\u00f3 T, et al. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. Atherosclerosis. 2017; 262: 8\u201313.","DOI":"10.1016\/j.atherosclerosis.2017.04.002"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024; 149: 354\u2013362.","DOI":"10.1161\/CIRCULATIONAHA.122.063460"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Kim HL, Kim SH. Pulse Wave Velocity in Atherosclerosis. Frontiers in Cardiovascular Medicine. 2019; 6: 41.","DOI":"10.3389\/fcvm.2019.00041"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Esposto S, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Progress in Cardiovascular Diseases. 2025; 92: 108\u2013117.","DOI":"10.1016\/j.pcad.2025.05.008"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, et al. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials. Journal of the American College of Cardiology. 2023; 82: 2251\u20132261.","DOI":"10.1016\/j.jacc.2023.10.007"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Willoughby JLS, Chan A, Sehgal A, Butler JS, Nair JK, Racie T, et al. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2018; 26: 105\u2013114.","DOI":"10.1016\/j.ymthe.2017.08.019"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Kallend D, Stoekenbroek R, He Y, Smith PF, Wijngaard P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. Journal of Clinical Lipidology. 2022; 16: 208\u2013219.","DOI":"10.1016\/j.jacl.2022.01.001"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clinic Proceedings. 2020; 95: 77\u201389.","DOI":"10.1016\/j.mayocp.2019.08.021"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Huang ZT, Zhang WH, Wang DZ, Zhang YJ, Duan YB, He XY, et al. Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database. Expert Opinion on Drug Safety. 2026; 25: 553\u2013560.","DOI":"10.1080\/14740338.2024.2446407"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Li B, Chen Y, Zhang Y, Qian M, Shan Q, Qian J, et al. Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS). Expert Opinion on Drug Safety. 2026; 25: 657\u2013668.","DOI":"10.1080\/14740338.2025.2468855"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"He Y, Guan X, Zhang Y, Zhu Z, Zhang Y, Feng Y, et al. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups. Expert Opinion on Drug Safety. 2024; 23: 1561\u20131569.","DOI":"10.1080\/14740338.2024.2348562"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Cai X, Peng S, Mu S, Lei S, Li J, Tang X, et al. Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database. Expert Opinion on Drug Safety. 2025; 24: 1067\u20131072.","DOI":"10.1080\/14740338.2024.2389989"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kosmas CE, Bousvarou MD, Tsamoulis D, Gianniou M, Papakonstantinou EJ, Rallidis LS. Novel RNA-Based Therapies in the Management of Dyslipidemias. International Journal of Molecular Sciences. 2025; 26: 1026.","DOI":"10.3390\/ijms26031026"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM48237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:17:51Z","timestamp":1788437871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM48237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03715-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm48237","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"48237"}}